Racial Differences in CYP3A4 Genotype and Survival Among Men Treated on Radiation Therapy Oncology Group (RTOG) 9202: A Phase III Randomized Trial

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 1, 2007, Pages 79-87

  Roach III, Mack ^a   De Silvio, Michelle ^b   Rebbick, Timothy ^c   Grignon, David ^d   Rotman, Marvin ^e   Wolkov, Harvey ^f   Fisher, Barbara ^g   Hanks, Gerald ^h   Shipley, William U ⁱ   Pollack, Alan ^h   Sandler, Howard ^j   Watkins Bruner, Deborah ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RTOG Headquarters   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f Radiological Associates of Sacramento Medical Group Inc   (United States)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

Genetic polymorphisms; Prostate cancer; Race; Radiotherapy

Indexed keywords

BIOCHEMICAL ENGINEERING; HEALTH CARE; POLYMORPHISM; RADIOTHERAPY;

GENETIC POLYMORPHISMS; PROSTATE CANCER; RACE;

GENETIC ENGINEERING;

ANDROGEN; CYTOCHROME P450 3A4; FLUTAMIDE; GOSERELIN;

AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; TREATMENT DURATION;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUTAMIDE; GENOTYPE; GOSERELIN; HUMANS; MALE; NEOPLASM PROTEINS; PRACTICE GUIDELINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SURVIVAL;

EID: 34547842092     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.03.008     Document Type: Article

References (19)

1. Jemal A., Murray T., Samuels A., et al. Cancer statistics 2003. CA Cancer J Clin 53 (2003) 5-26
2. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
3. Rebbeck T.R., Jaffe J.M., Walker A.H., et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90 (1998) 1225-1229
4. Cox D.R. Regression models and life tables. J Royal Statistical Soc 34 (1972) 187-202
5. Kaplan E.L., and Meier P. Non-parameteric estimation from incomplete observations. J Am Statistical Assoc 53 (1958) 457-481
6. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
7. Plummer S.J., Conti D.V., Paris P.L., et al. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 12 (2003) 928-932
8. Loukola A., Chadha M., Penn S.G., et al. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur J Hum Genet 12 (2004) 321-332
9. Gsur A., Feik E., and Madersbacher S. Genetic polymorphisms and prostate cancer risk. World J Urol 21 (2004) 414-423
10. Zeigler-Johnson C., Friebel T., Walker A.H., et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 64 (2004) 8461-8467
11. Paris P.L., Kupelian P.A., Hall J.M., et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 8 (1999) 901-905
12. Powell I.J., Zhou J., Sun Y., et al. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol 172 (2004) 1848-1852
13. Kittles R.A., Chen W., Panguluri R.K., et al. CYP3A4-V and prostate cancer in African Americans: Causal or confounding association because of population stratification. Hum Genet 110 (2002) 553-560
14. Roach III M. Hormonal therapy and radiotherapy for localized prostate cancer: Who, where and how long?. J Urol 170 (2003) S35-S40-S41
15. Roach III M., Lu J., Pilepich M.V., et al. Race and survival of men treated for prostate cancer on Radiation Therapy Oncology Group phase III randomized trials. J Urol 169 (2003) 245-250
16. Young C.D., Lewis P., Weinberg V., et al. The impact of race on freedom from PSA failure in prostate cancer patients treated with definitive radiation therapy. Semin Urol Oncol 18 (2000) 121-126
17. Roach M. Is race an independent prognostic factor for survival from prostate cancer?. J Natl Med Assoc 90 (1998) 713-719
18. Thompson I.M., Tangen C.M., Tolcher A., et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Institute 93 (2001) 219-225
19. Keshava C., McCanlies E.C., and Weston A. CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: A HuGE review. Am J Epidemiol 160 (2004) 825-841